94 related articles for article (PubMed ID: 27471841)
1. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Zaidi AH; Kosovec JE; Matsui D; Omstead AN; Raj M; Rao RR; Biederman RWW; Finley GG; Landreneau RJ; Kelly RJ; Jobe BA
Ann Surg; 2017 Jul; 266(1):91-98. PubMed ID: 27471841
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
4. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Zauderer MG; Alley EW; Bendell J; Capelletto E; Bauer TM; Callies S; Szpurka AM; Kang S; Willard MD; Wacheck V; Varghese AM
Invest New Drugs; 2021 Aug; 39(4):1081-1088. PubMed ID: 33660194
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
Jia N; Che X; Jiang Y; Zhu M; Yang T; Feng W
Gynecol Oncol; 2021 Sep; 162(3):788-796. PubMed ID: 34183163
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas.
Lee M; Wiedemann T; Gross C; Leinhäuser I; Roncaroli F; Braren R; Pellegata NS
Clin Cancer Res; 2015 Jul; 21(14):3204-15. PubMed ID: 25838390
[TBL] [Abstract][Full Text] [Related]
11. Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivation.
Kresty LA; Weh KM; Zeyzus-Johns B; Perez LN; Howell AB
Oncotarget; 2015 Oct; 6(32):33438-55. PubMed ID: 26378019
[TBL] [Abstract][Full Text] [Related]
12. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
Tang JC; An R; Jiang YQ; Yang J
Cancer Res Treat; 2017 Jul; 49(3):778-789. PubMed ID: 27857021
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.
Gibson MK; Zaidi AH; Davison JM; Sanz AF; Hough B; Komatsu Y; Kosovec JE; Bhatt A; Malhotra U; Foxwell T; Rotoloni CL; Hoppo T; Jobe BA
Ann Surg; 2013 Jul; 258(1):82-8. PubMed ID: 23108119
[TBL] [Abstract][Full Text] [Related]
14. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Santander S; Cebrián C; Esquivias P; Conde B; Esteva F; Jiménez P; Ortego J; Lanas A; Piazuelo E
Int J Oncol; 2012 Feb; 40(2):527-34. PubMed ID: 21971589
[TBL] [Abstract][Full Text] [Related]
18. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.
Kosovec JE; Zaidi AH; Omstead AN; Matsui D; Biedka MJ; Cox EJ; Campbell PT; Biederman RWW; Kelly RJ; Jobe BA
Oncotarget; 2017 Nov; 8(59):100421-100432. PubMed ID: 29245989
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo.
Lee M; Minaskan N; Wiedemann T; Irmler M; Beckers J; Yousefi BH; Kaissis G; Braren R; Laitinen I; Pellegata NS
Endocr Relat Cancer; 2017 Jan; 24(1):1-15. PubMed ID: 27811202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
